MARKET INSIGHTS INTO DRY AMD: FUTURE THERAPIES AND INDUSTRY FORECASTS

Market Insights into Dry AMD: Future Therapies and Industry Forecasts

Market Insights into Dry AMD: Future Therapies and Industry Forecasts

Blog Article

Market Insights into Dry AMD: Future Therapies and Industry Forecasts

Age-related macular degeneration (AMD) is a leading cause of vision loss in older adults, severely affecting their quality of life. Of the two primary forms of AMD—wet and dry—the latter represents approximately 85–90% of cases. Despite its high prevalence, treatment options for dry AMD have remained scarce, highlighting the need for innovative therapeutic solutions. DelveInsight’s latest report on the Dry AMD Market offers an in-depth analysis of the current treatment landscape, ongoing research, market size, and future growth prospects.

Dry AMD Therapeutics Market: Understanding & Treatment Dry AMD, or non-neovascular atrophic AMD, is characterized by gradual macula breakdown due to the buildup of drusen—yellow deposits beneath the retina. This progressive degeneration leads to central vision loss, making activities like reading and facial recognition increasingly difficult. Although dry AMD progresses more slowly than wet AMD, it lacks disease-modifying therapies, creating a significant challenge for clinical management.

Dry AMD Market Dynamics and Unmet Needs The global Dry AMD Market is set to experience substantial growth, driven by an aging population, growing awareness, and advancements in research. However, the key challenge remains the lack of effective treatments. For years, the standard care has mainly involved lifestyle changes, dietary supplements (such as the AREDS2 formulation), and supportive therapies. The absence of disease-modifying treatments has created a notable unmet need, prompting pharmaceutical companies to explore new therapeutic avenues.

Recent Advances and Dry AMD Pipeline Therapies Advancements in ophthalmology have led to several promising drug candidates in development for dry AMD. Some notable companies in the pipeline include:


  • Apellis Pharmaceuticals – Pegcetacoplan, a C3 complement inhibitor, recently received FDA approval for geographic atrophy (GA), a late-stage form of dry AMD.

  • IONIS Pharmaceuticals – IONIS-FB-LRx, an antisense therapy targeting the complement pathway.

  • Alkeus Pharmaceuticals – ALK-001, a modified vitamin A designed to slow retinal degeneration.

  • Gyroscope Therapeutics – GT005, a gene therapy candidate targeting the complement system.

  • Regenerative Medicine Companies – Investigating stem cell-based approaches for retinal restoration.


These advancements reflect a growing focus on addressing the complement cascade, inflammation, and oxidative stress—critical factors in the progression of dry AMD.

Dry AMD Market Size and Growth Forecast DelveInsight’s analysis suggests that the Dry AMD Market will experience significant growth over the coming decade. Key factors driving this expansion include:

  • Rising Prevalence: As the aging population increases, the number of individuals affected by dry AMD is expected to rise.

  • Regulatory Approvals: The approval of new therapies like Pegcetacoplan represents a major shift in dry AMD treatment.

  • Investment in R&D: Pharmaceutical and biotech companies are heavily investing in dry AMD research, spurring innovation in treatment options.

  • Collaborations and Partnerships: Strategic collaborations between biotech firms, academia, and regulatory bodies are accelerating drug development and commercialization.


Challenges and Future Outlook Despite these promising advancements, the Dry AMD Market faces several challenges, including:

  • High Development Costs: The complexity of clinical trials and lengthy approval processes contribute to high research costs.

  • Patient Accessibility: Affordability and reimbursement policies may limit the adoption of emerging therapies.

  • Limited Awareness: Many patients remain unaware of dry AMD and its treatments, underscoring the need for improved education and early detection efforts.


Looking ahead, the Dry AMD Market is expected to rapidly evolve, with new therapies reshaping treatment options. As pharmaceutical companies address existing gaps, a shift from supportive care to disease-modifying treatments is anticipated, significantly improving patient outcomes.

Conclusion The Dry AMD Market is at a critical turning point, with groundbreaking innovations paving the way for enhanced treatment options. As the pipeline progresses and new therapies gain regulatory approval, the future looks promising for individuals suffering from dry AMD. DelveInsight’s comprehensive analysis provides valuable insights into market trends, key players, and the evolving competitive landscape, helping stakeholders navigate this dynamic sector.

Latest Reports Offered By DelveInsight:-
Non Alcoholic Fatty Liver Disease Nafld Market | Xerostomia Market | Adrenal Cortex Neoplasms Market | Arthroscopy Devices Market | Bone Anchored Hearing Systems Market | Cough Assisted Device Market | Neuroblastoma Market | Pharma Licensing Services | Allergic Rhinitis Market | Alpha-mannosidosis Market | Bronchopulmonary Dysplasia Market | Burkitt Lymphoma Market | Chronic Rhinosinusitis Market | Chronic Rhinosinustis Market | Contraceptive Devices Market | Febrile Neutropenia Market | Hepatitis B Virus Market | Minimal Residual Disease Market | Non-st Segment Elevation Acute Coronary Syndromes Market | Nsclc Market | Prefilled Syringes Market | Walking Impairment In Multiple Sclerosis Market | Acute On Liver Failure Market

Report this page